T. Rowe Price Associates
EVH icon

T. Rowe Price Associates’s Evolent Health EVH Stock Holding History

T. Rowe Price Associates’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$342K Buy
149,821
+15,408
+11% +$48.9K ﹤0.01% 2623
2025
Q4 		$538K Buy
134,413
+18,653
+16% +$104K ﹤0.01% 2363
2025
Q3 		$980K Buy
115,760
+9,998
+9% +$97K ﹤0.01% 2082
2025
Q2 		$1.19M Buy
105,762
+7,156
+7% +$65.7K ﹤0.01% 1903
2025
Q1 		$934K Sell
98,606
-645,839
-87% -$6.52M ﹤0.01% 1993
2024
Q4 		$8.38M Buy
744,445
+28,540
+4% +$502K ﹤0.01% 1181
2024
Q3 		$20.2M Sell
715,905
-7,054
-1% -$182K ﹤0.01% 990
2024
Q2 		$13.8M Buy
722,959
+5,625
+0.8% +$144K ﹤0.01% 1043
2024
Q1 		$23.5M Buy
717,334
+75,376
+12% +$2.41M ﹤0.01% 940
2023
Q4 		$21.2M Buy
641,958
+4,080
+0.6% +$115K ﹤0.01% 941
2023
Q3 		$17.4M Sell
637,878
-212,383
-25% -$5.9M ﹤0.01% 951
2023
Q2 		$25.8M Buy
850,261
+6,317
+0.7% +$204K ﹤0.01% 870
2023
Q1 		$27.4M Sell
843,944
-3,185
-0.4% -$101K ﹤0.01% 840
2022
Q4 		$23.8M Buy
847,129
+94,043
+12% +$2.7M ﹤0.01% 863
2022
Q3 		$27.1M Buy
753,086
+715,327
+1,894% +$25.2M ﹤0.01% 823
2022
Q2 		$1.16M Buy
37,759
+3,382
+10% +$98.6K ﹤0.01% 1825
2022
Q1 		$1.11M Buy
34,377
+4,340
+14% +$114K ﹤0.01% 1953
2021
Q4 		$831K Sell
30,037
-5,035
-14% -$144K ﹤0.01% 2119
2021
Q3 		$1.09M Sell
35,072
-1,500
-4% -$36K ﹤0.01% 2024
2021
Q2 		$772K Sell
36,572
-661
-2% -$13.2K ﹤0.01% 2178
2021
Q1 		$752K Sell
37,233
-3,971
-10% -$75.5K ﹤0.01% 2183
2020
Q4 		$661K Buy
41,204
+7,900
+24% +$104K ﹤0.01% 2117
2020
Q3 		$413K Sell
33,304
-19,100
-36% -$225K ﹤0.01% 2169
2020
Q2 		$373K Sell
52,404
-4,438
-8% -$29.7K ﹤0.01% 2175
2020
Q1 		$309K Buy
56,842
+787
+1% +$7.03K ﹤0.01% 2179
2019
Q4 		$507K Buy
56,055
+36,482
+186% +$296K ﹤0.01% 2146
2019
Q3 		$141K Buy
19,573
+362
+2% +$2.6K ﹤0.01% 2424
2019
Q2 		$153K Buy
19,211
+310
+2% +$3.67K ﹤0.01% 2438
2019
Q1 		$238K Buy
18,901
+200
+1% +$3.17K ﹤0.01% 2363
2018
Q4 		$373K Buy
18,701
+328
+2% +$7.59K ﹤0.01% 2194
2018
Q3 		$522K Buy
18,373
+597
+3% +$14.2K ﹤0.01% 2135
2018
Q2 		$374K Sell
17,776
-5,077
-22% -$96.1K ﹤0.01% 2268
2018
Q1 		$326K Buy
22,853
+285
+1% +$4.08K ﹤0.01% 2263
2017
Q4 		$278K Buy
22,568
+6,760
+43% +$95.3K ﹤0.01% 2308
2017
Q3 		$281K Buy
15,808
+100
+0.6% +$2.06K ﹤0.01% 2302
2017
Q2 		$398K Sell
15,708
-936
-6% -$22.5K ﹤0.01% 2144
2017
Q1 		$371K Buy
16,644
+13
+0.1% +$250 ﹤0.01% 2168
2016
Q4 		$246K Buy
+16,631
New +$328K ﹤0.01% 2315

Other funds holding EVH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates's EVH Position: Q1 2026 in Review

T. Rowe Price Associates increased its Evolent Health (EVH) stake by 11% in Q1 2026, buying an estimated $48.9K and bringing the position to 149,821 shares worth $342K. The position accounts for ﹤0.01% of the portfolio, ranked #2623.

T. Rowe Price Associates first reported a position in EVH in Q4 2016 and has held it in 38 quarters since. The position peaked at $27.4M in Q1 2023. 191 funds tracked by Wall St. Rank hold EVH as of Q1 2026.

  • T. Rowe Price Associates held 149,821 shares of Evolent Health worth $342K as of Q1 2026.
  • T. Rowe Price Associates bought 15,408 Evolent Health shares in Q1 2026, an estimated $48.9K.
  • Evolent Health made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2623 holding.
  • T. Rowe Price Associates first reported a position in Evolent Health in Q4 2016 and has held it in 38 quarters since.
  • T. Rowe Price Associates's Evolent Health position peaked at $27.4M in Q1 2023.
  • 191 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.